Selecta is a biotechnology company developing novel drugs that use immune modulating nanomedicines to generate antigen-specific immune responses to prevent and treat disease. The company is applying its SVP platform to create first-in-class antigen-specific tolerogenic immunotherapeutics that are designed to prevent undesired immune responses in auto-immune diseases, biologic therapy and allergies. NASDAQ: SELB